sglt2 inhibitors and glp-1 receptor agonists Combining in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique View of Diabetes medications with
Description
Am I a good candidate for GLP-1s
Lau J, Bloch P, Schffer L, Pettersson I, Spetzler J, Kofoed J, et al
For a more accurate assessment, large-scale pharmacokinetic/pharmacodynamic (PK/PD) studies need to be conducted
The question isn't whether you'll lose some lean mass
Published 2025 Jan 8
References 1 American Diabetes Association Professional Practice Committee
